May 01, 2026

Pre-Assembly Vs Final Assembly: Why Insulin Pen Manufacturing Requires An Integrated Approach

Leave a message

The manufacturing of insulin pens and autoinjectors is a highly complex process that is fundamentally divided into two distinct stages: Pre-Assembly and Final Assembly. While these stages handle different materials and require different engineering disciplines, treating them as isolated silos is one of the most common-and costly-mistakes pharmaceutical companies make when scaling up production.
To understand why an integrated approach is critical, we must first look at the distinct challenges of each stage.
 

The Challenge of Pre-Assembly

 

Pre-assembly is a purely mechanical process. It involves assembling the plastic components of the pen-the housing, the dosing mechanism, the spring, and the needle hub.
 
•Speed & Precision: This stage operates at high speeds. Modern pre-assembly equipment, such as those provided by DROFEN MACHINERY, operates at around 160 pens per minute.
•Plastic-to-Plastic Tolerances: The primary challenge is managing the micro-tolerances of molded plastic parts. If the dosing mechanism is assembled with even a fraction of a millimeter of misalignment, the final device will fail to deliver the correct dose.
 

The Challenge of Final Assembly

 

Final assembly is where the pharmaceutical product meets the medical device. It involves inserting the filled glass cartridge (containing the insulin or GLP-1 drug) into the pre-assembled pen body, attaching the final closures, and performing functional testing.
•Drug Handling & Cleanliness: This stage requires strict adherence to GMP standards. The equipment must handle fragile glass cartridges without causing micro-cracks and must operate in a highly controlled cleanroom environment.
•Speed Matching: Final assembly lines typically operate at around 80 units per minute, carefully calibrated to match the output of the upstream filling lines.
 

The Integration Gap: Why Sourcing Separately Fails

 

Historically, some companies have purchased pre-assembly machines from specialized automation vendors and final assembly lines from traditional pharma OEM suppliers. This creates a massive "Integration Gap."
When the pre-assembled pens arrive at the final assembly line, any slight deviation in the plastic assembly can cause the final assembly machine to jam, crush the glass cartridge, or produce a defective device. When this happens, the pre-assembly vendor blames the final assembly machine, and the final assembly vendor blames the pre-assembled parts.
 

The Solution: The Integrated System Supplier

 

To eliminate the Integration Gap, pharmaceutical companies are increasingly turning to integrated system suppliers who design and deliver both stages.
By sourcing both the 160 ppm pre-assembly equipment and the 80 ppm final assembly line from a single partner like DROFEN MACHINERY, manufacturers gain three distinct advantages:
 
1.Unified Platform Coordination: The supplier ensures that the tolerances of the pre-assembled pen perfectly match the gripping and insertion mechanisms of the final assembly line.
2.Single Source of Accountability: There is no finger-pointing. The supplier is responsible for the yield and performance of the entire process, from empty plastic components to the finished, tested device.
3.Streamlined Validation (Q1-Q8): Validating two separate systems from two different vendors doubles the RA/QA workload. An integrated supplier provides a unified, GAMP5 and 21 CFR Part 11 compliant documentation package for the entire line, drastically reducing time-to-market.
 

Conclusion

 

As the demand for injectable therapies grows, the margin for error in manufacturing shrinks. By choosing an integrated project-delivery partner like DROFEN MACHINERY, CDMOs and pharma companies can bridge the gap between mechanical pre-assembly and pharmaceutical final assembly, ensuring a smoother, faster, and more reliable path to commercial production.
 

Related Technical Resources

 

 
Send Inquiry